A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

This study is testing a new cancer vaccine called EO2463, alone or combined with other treatments, for patients with slow-growing (indolent) non-Hodgkin lymphoma — including follicular lymphoma (FL) and marginal zone lymphoma (MZL). The vaccine is designed to train the immune system to attack lymphoma cells. **You may be eligible if you:** - Have been diagnosed with grade 1, 2, or 3A follicular lymphoma or marginal zone lymphoma - Are in good enough health to participate (ECOG performance status 0–2) - Have either relapsed/refractory disease after at least one prior treatment, OR are newly diagnosed with low tumor burden and not currently needing standard treatment **You may NOT be eligible if you:** - Have high-grade (aggressive) lymphoma - Have already received multiple lines of intensive therapy that have left your organs significantly impaired - Have other conditions that make you ineligible per study criteria Talk to your doctor to see if this trial is right for you.